GenEditBio

GenEditBio is a gene editing company that develops precision gene-editing technology and a pipeline of programmable gene therapy products for treating genetic diseases. The company operates across multiple therapeutic areas including cardiac and vascular disorders, rare diseases, ophthalmology, and drug delivery, leveraging advanced gene-editing platforms to develop targeted therapies for conditions with significant unmet medical need. GenEditBio's approach focuses on creating programmable gene therapy products that can be customized to address specific genetic mutations underlying disease, enabling precision medicine approaches for patient populations that currently lack effective treatment options. The company's technology platform encompasses gene-editing tools, delivery systems, and therapeutic development capabilities, supporting a diversified pipeline across cardiac and vascular disorders, corneal disorders, and rare genetic conditions. By integrating gene editing with drug delivery technologies, GenEditBio aims to overcome the challenges of delivering gene-editing machinery to target tissues safely and effectively, which remains a critical bottleneck in the gene therapy field. The company's work in genomics enabling technologies positions it to develop both standalone therapeutics and platform technologies that could be applied across multiple disease areas. Founded in 2021 and headquartered in Hong Kong, China, GenEditBio has raised $10.0M in seed funding from investors including Gobi Partners and Qiming Venture Partners. The team comprises 22 employees.